ASU bioengineer makes key contribution to cancer treatment research

December 17, 2012

Michael Caplan shares authorship of a paper on cancer treatment research published this week in the prestigious Proceedings of the National Academy of Sciences journal.

Caplan is an associate professor in the School of Biological and Health Systems Engineering, one of Arizona State University's Ira A. Fulton Schools of Engineering.

The paper focuses on results of research led by Robert Gillies at the H. Lee Moffitt Cancer Center and Research Institute. Caplan has been collaborating on the project since 2005.

The research team explored potential methods of making therapeutic biomaterials stick only to in the body – without threatening to damage healthy – by combining two short amino acid chains, each of which stick to different molecules on the surface of .

Researchers looked at whether these therapeutics could accumulate preferentially in the tumor if the targets for the two components were present, and compared that to the accumulation when only one of the targets was present.

The paper detailing their findings is titled "Heterobivalent ligands -surface receptor combinations in vivo."

Caplan explains: "We take two peptides – think short proteins –and link them together with a short linker, a linker. The paper is about a targeting molecule that has only two peptides that are different, called heterobivalent ligands."

The receptors in the paper's title refer to "transmembrane proteins on cells – proteins that go all the way through the cell membrane," Caplan says. "Certain receptor types are expressed more on cancer cells than on normal cells. Those receptors are the targets. In this case we have targeted CCK2R (CCK receptor) and MC1R (melacortanin receptor). There is a peptide that will bind to each receptor, and these are linked together to make the heterobivalent ligand."

In this way the researchers showed that combining these two components allows the therapeutics to accumulate specifically in the targeted tumor but not in other body tissues.

The results point to ways to provide effective using lower doses of medicines, which would cause fewer or less intense negative side effects, Caplan says.

Caplan worked on biophysical aspects of the research, producing mathematical modeling showing precisely how the molecules behave. That helped fellow researchers understand why certain molecules worked better than others for the therapeutics delivery and treatment processes.

In addition to Gillies and Caplan, authors of the paper are Liping Xu and David L. Morse of the Moffitt Center,  and Jatinder S. Josan, Victor J. Hruby, Eugene A. Mash, Josef Vagner and Ronald Lynch of the University of  Arizona.

Explore further: Researchers help in search for new ways to image, therapeutically target melanoma

More information: www.pnas.org/content/early/201 … 762109.full.pdf+html

Related Stories

Researchers help in search for new ways to image, therapeutically target melanoma

November 3, 2011
Because the incidence of malignant melanoma is rising faster than any other cancer in the U.S., researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues at Tampa-based Intezyne Technologies, Inc., Western Carolina ...

Bioethicist challenges Bachmann on vaccine claim

September 16, 2011
(AP) -- A prominent bioethicist has offered $10,000 to charity if Republican presidential candidate Michele Bachmann can prove her claim that a vaccination caused mental retardation.

New universal platform for cancer immunotherapy developed

March 5, 2012
(Medical Xpress) -- Researchers from the Perelman School of Medicine at the University of Pennsylvania report this month in Cancer Research a universal approach to personalized cancer therapy based on T cells. It is the first ...

Combination peptide therapies might offer more effective, less toxic cancer treatment

August 16, 2012
Two studies suggest that two peptide agents used either together or individually with a low-dose of a standard chemotherapy drug might offer more effective cancer therapy than current standard single-drug treatments.

Cell receptor could allow measles virus to target tumors

August 25, 2011
Canadian researchers have discovered that a tumor cell marker is a receptor for measles virus, suggesting the possible use of measles virus to help fight cancer. Their findings appear in the Open Access journal PLoS Pathogens ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.